TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) Valuation Check After Launch Of GAMMAGARD LIQUID ERC In The United States
Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after launching GAMMAGARD LIQUID ERC in the U.S., a ready to use, low IgA immunoglobulin therapy that broadens treatment options for primary immunodeficiency patients.
See our latest analysis for Takeda Pharmaceutical.
Beyond this product launch, Takeda’s share price has been firm, with a 19.09% 90 day share price return and a 32.56% 1 year total shareholder return. This may indicate building momentum rather than fading interest.
If...